UNGASS COUNTRY PROGRESS REPORT

The Netherlands
and Parts of the Dutch Kingdom in the Caribbean

Reporting period: January 2010–December 2011

Submission date: 31 March 2012
**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Ministry of) VWS</td>
<td>(Ministry of) Health, Welfare and Sport</td>
</tr>
<tr>
<td>ACS</td>
<td>‘Aanvullende Curatieve Soa-bestrijding’</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>ASH</td>
<td>‘Aanvullende Seksualiteits hulpverlening’</td>
</tr>
<tr>
<td>ASG</td>
<td>‘Aanvullende regeling Seksuele Gezondheidszorg’</td>
</tr>
<tr>
<td>cART</td>
<td>Combination antiretroviral treatment</td>
</tr>
<tr>
<td>CID</td>
<td>Centre for Infectious Disease Control</td>
</tr>
<tr>
<td>CVZ</td>
<td>‘College voor Zorgverzekeringen’</td>
</tr>
<tr>
<td>ECDC</td>
<td>European Centre for Disease Prevention and Control</td>
</tr>
<tr>
<td>GDP</td>
<td>Gross domestic product</td>
</tr>
<tr>
<td>GGD</td>
<td>Municipal health service</td>
</tr>
<tr>
<td>GP</td>
<td>General practitioner</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>IDU</td>
<td>Intravenous drug use</td>
</tr>
<tr>
<td>IGZ</td>
<td>The Netherlands Health Care Inspectorate</td>
</tr>
<tr>
<td>MSM</td>
<td>Men who have sex with men</td>
</tr>
<tr>
<td>NCPI</td>
<td>National Composite Policy Index</td>
</tr>
<tr>
<td>NGO</td>
<td>Non-governmental organisation</td>
</tr>
<tr>
<td>PLWHA</td>
<td>People living with HIV/AIDS</td>
</tr>
<tr>
<td>RIVM</td>
<td>National Institute for Public Health and the Environment</td>
</tr>
<tr>
<td>SHM</td>
<td>‘Stichting HIV Monitoring’</td>
</tr>
<tr>
<td>SRHR</td>
<td>Sexual and reproductive health and rights</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually transmitted infection</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>The Joint United Nations Programme on HIV/AIDS</td>
</tr>
<tr>
<td>UNFPA</td>
<td>United Nations Population Fund</td>
</tr>
<tr>
<td>WBMV</td>
<td>‘Wet op Bijzondere Medische Verrichtingen’</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
# I. Table of contents

## II. Status at a glance

- Writing process ................................................................. 4
- Status of the epidemic ......................................................... 4
- Policy and programmatic response ......................................... 5
- GARPR/UNGASS indicator data .............................................. 6

## III. Overview of the AIDS epidemic

- Estimation of the HIV epidemic ............................................ 6
- Registration of Stichting HIV Monitoring (SHM) ..................... 7
- Surveillance based on data from STI centres ......................... 10
- Screening programmes ......................................................... 11
- Specific studies in high-risk populations ............................... 11

## IV. National response to the AIDS epidemic

- Prevention ........................................................................... 12
- Care, treatment and support ............................................... 13
- Knowledge and behaviour change ....................................... 17
- Impact alleviation .................................................................. 18

## V. Best practices ................................................................. 18

## VI. Major challenges and remedial actions .......................... 19

## VII. Support from the country’s development partners ........... 20

## VIII. Monitoring and evaluation environment ....................... 20

## IX. Parts of the Dutch Kingdom in the Caribbean ................ 21

## X. Contributions to international HIV/AIDS response .......... 21

## ANNEXES ........................................................................... 23
II. Status at a glance

Writing process

This Country Progress Report for the Global AIDS Response Progress Reporting 2012 is based on previous reports in connection with the 2001 'Declaration of Commitment on HIV/AIDS' as well as the 2004 'Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia'. The report is compiled by the Ministry of Health Welfare and Sport (VWS) and the Centre for Infectious Disease Control (CIb) of the National Institute for Public Health and the Environment (RIVM) with contributions from other ministries and stakeholders. The preparation of the report has been subject of discussion during a meeting of the Dutch 'STI and sexual health platform’ where civil society stakeholders are represented. STI AIDS Netherlands, a non-governmental organisation (NGO) and an expertise STI centre for HIV and other STI, has consolidated the input from other NGOs. In particular, this involved completing part B of the National Composite Policy Index (NCPI) questionnaire and commenting on a final draft version of this Country Progress Report.

Status of the epidemic

The HIV epidemic in The Netherlands is evolving slowly and its characteristics have not changed substantially during the reporting period 2010-2011.

The Netherlands has a concentrated HIV epidemic, i.e. a low prevalence of HIV infection in the general population but a higher prevalence in specific sub-populations. Primary high-risk sub-populations are men who have sex with men (MSM) and migrants from high-prevalence countries. The epidemic in the Netherlands is primarily fuelled by transmission among MSM.

The number of HIV-infected individuals (15-70 years) living in the Netherlands on 1 January 2008 has been estimated to be 21,500 (19,000-24,000). This represents an increase of about 10% in comparison with the previous estimate in 15-49-year-olds from 2005. The estimated HIV infection prevalence remained at 0.2% in the adult population. Of the HIV infections in January 2008, 55% were estimated to be attributed to MSM transmission, 40% to heterosexual contacts and 4% to intravenous drug use (IDU).

In June 2011, 18,735 patients at HIV treatment centres in the Netherlands were registered by the Stichting HIV Monitoring (SHM). The total number includes 1,408 (8%) new registered patients in the Netherlands during the previous year. Of 14,610 (79%) patients alive in active follow-up in the Netherlands as of June 2011, 14,455 (99%) were adults (≥18 years) and 155 (1%) were children and adolescents. Of the 14,610 patients, 79% were male and 21% were female. The median age was 45 years (interquartile range 38-52 years). The HIV patient population is ageing and currently 32% of the patients is 50 years or older.

Of adult patients in follow-up in the Netherlands as of June 2011, the largest group was MSM (58%). Heterosexuals accounted for 31% of patients (16% of men and 86% of women). Heterosexuals included a considerable proportion of individuals originating from other countries than the Netherlands (32% originated from the Netherlands). The most common
area of origin was sub Saharan Africa (42% of heterosexuals). IDU constituted 4% of patients.

Until 2010, 8,345 AIDS cases and 5,115 deaths among HIV patients have been registered in the Netherlands. The AIDS incidence and mortality among HIV-infected individuals appear to exhibit a slight decline in recent years\(^4, 5\).

The status of the epidemic is detailed under the prescribed headings of section 'III. Overview of the AIDS epidemic'.

**Policy and programmatic response**

During the reporting period 2010-2011, the overall HIV/AIDS-related policy and programmatic frameworks in the Netherlands have remained largely unaltered, notwithstanding a number of important developments. Most important, in December 2011 we have published our first national policy plan STI/HIV 2012-2016 “To renew and reinforce” in which the Dutch HIV/STI policy for the coming years is described. The plan is developed by the Centre for Infectious Disease Control in close collaboration with the Ministry Health Welfare and Sport, and all other stakeholders involved in HIV and STI control ((sub-)national (non-)governmental stakeholders).

HIV/AIDS policy is primarily a responsibility of the Ministry of VWS. It should be recognised, however, that policy development in the realms of HIV/AIDS depends on the collaboration of a range of (sub-)national (non-)governmental stakeholders. Similarly, the implementation of HIV/AIDS policy-related activities relies on collaboration among a multitude of stakeholders.

The Dutch government seeks to place HIV/AIDS policy in a larger framework of sexual health. The national STI/HIV plan builds upon previous policy reports, such as the sexual health policy document of 2009\(^6\). Of further influence is the national note on health policy (Landelijke nota gezondheidsbeleid, 2011\(^7\)), which forms the basis for the current lifestyle policy, addressing multiple health issues, including sexual health. This national STI/HIV plan outlines central principles of Dutch HIV/AIDS policy, such as the importance of prevention, the importance of linkage between prevention and care as well as efforts to ensure low-threshold access to testing and treatment. The national plan further underlines the crucial contributions of different (non-)governmental stakeholders in the area of STI/HIV. The responsibilities and relations of these organisations are described in order to reduce overlap and gaps. The division of responsibilities are mainly organized by risk groups and serves to promote tailor-made approaches based on appropriate expertise.

Based on STI/HIV epidemiology in its behavioural context, the following risk populations are identified in the national STI/HIV plan:
- Young people
- Men who have sex with men (MSM)
- Migrants (primarily those from HIV-endemic countries)
- HIV-infected persons


\(^7\) VWS, May 2011 National health policy document “Gezondheid Dichtbij”
Furthermore, the following points of special interest for STI/HIV control and policy are acknowledged:
- Lifestyle policy (referring to the national note\textsuperscript{8})
- Antibiotic resistance to gonorrhoea
- Linkage between additional health care and regular health care settings
- Linkage between prevention and care
- Quality assurance
- Collaboration and control
The policy and programmatic responses are detailed under the prescribed headings of section IV. National response to the AIDS epidemic.

**GARPR/UNGASS indicator data**

For historical reasons and considering local contexts, such as existing set-up of surveillance and monitoring activities, data and/or information are not consistently available to allow for a complete representation of GARPR/UNGASS indicators as per specific formats of the UNGASS reporting guidelines. However, relevant data and/or information in this regard are presented in this report.

**III. Overview of the AIDS epidemic**

The Netherlands has a concentrated HIV epidemic, i.e. a low prevalence of HIV infection in the general population but a higher prevalence in specific sub-populations\textsuperscript{9}. Primary high-risk sub-populations are MSM and migrants from high-prevalence countries. The epidemic in the Netherlands is primarily fuelled by transmission among MSM.

**Estimation of the HIV epidemic\textsuperscript{10}**

The number of HIV-infected individuals (15-70 years) living in the Netherlands on 1 January 2008 has been estimated to be 21,500 (19,000-24,000) (Figure 1). This represents an increase of about 10\% in comparison with the previous estimate in 15-49-year-olds from 2005. The estimated HIV infection prevalence remained at 0.2\% in the adult population.

Of the HIV infections in January 2008, 55\% were estimated to be attributed to MSM transmission, 40\% to heterosexual contacts and 4\% to IDU. Estimation of the HIV prevalence in risk groups in the Netherlands in 2008 yielded the following preliminary results: MSM 5.1\%, IDU 7.1\%, migrants from sub Saharan Africa 3.1\%, migrants from the Caribbean 0.4\%, female sex workers 1.8\%, and for the remaining population 0.02\%.

About 60\% (53-67\%) of people infected with HIV was estimated to have been diagnosed. The estimated proportion of diagnosed infections exhibited geographical variations, 85\% in Amsterdam, 54\% in Rotterdam and 53\% in the rest of the country. The estimated proportion of diagnosed infections also differed by risk group. Of HIV-infected MSM, 65\% were estimated to have been diagnosed. Of infected sex workers, 34\% were estimated to have been diagnosed. In the IDU population, the estimated proportion of diagnosed individuals varied between 57\% in Rotterdam to 91\% in Amsterdam.

\textsuperscript{8} VWS, May 2011 National health policy document "Gezondheid Dichtbij"
\textsuperscript{10} RIVM/CIb. 2009. National estimate of HIV prevalence in the Netherlands: comparison and applicability of different estimation tools.
With regard to migrant populations, 50% of infected migrants from sub-Saharan Africa and 55% of infected migrants from the Caribbean were estimated to have been diagnosed. In general, women were more likely to have been diagnosed than men, probably due to antenatal screening and differences in health care seeking behaviour.

**Figure 1.** Estimated number of people living with HIV-infection, The Netherlands, 1973-2013 (Source: RIVM/CIb)

Registration of Stichting HIV Monitoring (SHM)

HIV infection is not notifiable by law in the Netherlands. However, data about HIV infected individuals are collected by SHM as part of routine health care for HIV patients. Treatment data for all HIV patients receiving care at 25 HIV treatment centres are collected.

Up to December 2010, 17,868 patients at HIV treatment centres in the Netherlands were registered by SHM of whom 90.4% are still alive. In 2010, 1,256 new HIV patients were reported in care of whom 826 were newly diagnosed in 2010 (incomplete due to reporting delay). Of the 17,868 registered patients, 2.4% (n=436) were 18 years or younger. Of all registered patients, 21% were female. The proportion of MSM accounting for new HIV patients in care was 66% in 2010. The proportion of heterosexuals was 28%. The HIV patient population is ageing; of all registered patients 11.4% are 50 years or older. For patients diagnosed in 2010, this percentage was 20.5%.

Table 1 describes basic characteristics of registered HIV-infected patients in the Netherlands as of December 2010. The largest group was MSM (56%). Heterosexuals accounted for 32% of patients (18% of men and 85% of women). Heterosexuals included a considerable proportion of individuals originating from other countries than the Netherlands (53%). The most common areas of origin were sub Saharan Africa, Western Europe and Latin America. IDU constituted 4% of patients (4% of men and 5% of women).

In 2010, 66% of diagnosed cases were MSM. Of all registered HIV-infected MSM, 83% were of Dutch origin.

---

Table 1. Characteristics of all registered HIV-infected patients, the Netherlands, Dec 2010 (Source: SHM)

<table>
<thead>
<tr>
<th>Category</th>
<th>Men</th>
<th>Women</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>All</td>
<td>14,133</td>
<td>79</td>
<td>3,735</td>
</tr>
<tr>
<td>Transmission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSM*</td>
<td>10,005</td>
<td>71</td>
<td>10,005</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>2,486</td>
<td>18</td>
<td>3,181</td>
</tr>
<tr>
<td>IDU*</td>
<td>511</td>
<td>4</td>
<td>184</td>
</tr>
<tr>
<td>Blood (products)</td>
<td>130</td>
<td>1</td>
<td>75</td>
</tr>
<tr>
<td>Vertical</td>
<td>102</td>
<td>0.7</td>
<td>96</td>
</tr>
<tr>
<td>Other / unknown</td>
<td>899</td>
<td>6</td>
<td>195</td>
</tr>
<tr>
<td>Age category (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-14</td>
<td>133</td>
<td>1</td>
<td>104</td>
</tr>
<tr>
<td>15-19</td>
<td>198</td>
<td>1</td>
<td>238</td>
</tr>
<tr>
<td>20-24</td>
<td>1,011</td>
<td>7</td>
<td>577</td>
</tr>
<tr>
<td>25-29</td>
<td>2,037</td>
<td>14</td>
<td>847</td>
</tr>
<tr>
<td>30-39</td>
<td>5,387</td>
<td>38</td>
<td>1,258</td>
</tr>
<tr>
<td>40-49</td>
<td>3,578</td>
<td>25</td>
<td>461</td>
</tr>
<tr>
<td>50-59</td>
<td>1,402</td>
<td>10</td>
<td>183</td>
</tr>
<tr>
<td>60-69</td>
<td>324</td>
<td>2</td>
<td>56</td>
</tr>
<tr>
<td>70+</td>
<td>61</td>
<td>0.4</td>
<td>9</td>
</tr>
<tr>
<td>Region of origin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>9,162</td>
<td>64</td>
<td>1,013</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>1,332</td>
<td>9</td>
<td>1,714</td>
</tr>
<tr>
<td>Western Europe</td>
<td>1,017</td>
<td>7</td>
<td>197</td>
</tr>
<tr>
<td>Latin America</td>
<td>989</td>
<td>7</td>
<td>315</td>
</tr>
<tr>
<td>Caribbean</td>
<td>469</td>
<td>3</td>
<td>195</td>
</tr>
</tbody>
</table>

* MSM, men who have sex with men; IDU, intravenous drug use

Figure 2. Proportion of annual HIV cases in care by transmission risk group and year of diagnosis, the Netherlands, 1996-2010 (data for year 2010 are incomplete) (Source: SHM)
Until 2010, 8,345 AIDS cases and 5,115 deaths among HIV patients have been registered in the Netherlands. The AIDS incidence and mortality among HIV-infected individuals appear to exhibit a slight decline in recent years\textsuperscript{12,13}. (figure 3)

**Figure 3.** Number of AIDS cases and deaths among HIV patients, 1983-2010 (data for year 2010 are incomplete) (Source: SHM, RIVM)

The majority of the patients in care, 85% had started with combination antiretroviral treatment (cART), whilst 15% were not yet treated, probably because there was no indication to do so. The most frequently prescribed regimes, which accounted for 43% of all treatment combinations, were a combination of tenofovir/emtricitabine and either efavirenz or nevirapine. In 2010, these 2 combinations accounted for 41% of all regimes. Tenofovir as part of any treatment combination was used by 73% of the patients, whilst emtricitabine was used by 64%, efavirenz by 35%, and nevirapine by 25%. The costs for antiretrovirals amount to about €141 million per year in 2010\textsuperscript{14}.

The increase in CD4 counts at diagnosis and a decrease in proportion of late diagnoses suggests that patients are testing positive for HIV increasingly earlier in the course of their infection. This earlier diagnosis is also apparent in the observed increase from 10% in 1996 to 37% in 2010 in the proportion of MSM who were diagnosed with a recent infection (defined as 1.5 years, at most, between the last negative HIV test and the first positive test). Diagnosis with a recent infection was less common in older MSM. Amongst the MSM diagnosed in 2008 or later, 48% of the diagnosed HIV infections were classified as recent amongst those aged 18 to 24 years, but only 24% were recent infections in those aged 55 years or older. Also, the proportion of recent infections amongst heterosexuals appeared to increase, but to a more moderate extent (5% in 1996 to 10% in 2010).

Additional information is available in the reports of SHM that are published in English on an annual basis\textsuperscript{15}.

\textsuperscript{14} Source: Stichting Farmaceutische Kengetallen (SFK)
\textsuperscript{15} SHM: http://www.hiv-monitoring.nl/
Surveillance based on data from STI centres\textsuperscript{16}

An STI/HIV surveillance system is in place where eight coordinating municipal health services (GGD) report STI/HIV-related data and information to the RIVM/CIb. The system is based on 29 STI centres with nationwide coverage. The STI centres cater for high-risk groups and people who wish to remain anonymous. They provide low-threshold and free of charge STI/HIV testing and care (see section ‘IV. National response to the AIDS epidemic’).

In 2010, 375 individuals were newly diagnosed with HIV at the STI clinics in the Netherlands. Of these infections, 317 (85\%) occurred in MSM, 30 (8\%) in heterosexual men and 28 (7\%) among women. The positivity rate among MSM decreased further to 2.0\% (in 2009 2.4\%, in 2008 3.0\%), among heterosexual men and women it remained 0.1\%. Among heterosexual STI clinic attendees the HIV positivity rate was highest among those from sub-Saharan African origin (heterosexual men 1.3\%, women 1.5\%, MSM 6.0\%). Among MSM, HIV positivity rate was highest among MSM aged 30-34 years (2.8\%).

Among newly diagnosed HIV-positive MSM, 26\% was concurrently diagnosed with chlamydia and 21\% with gonorrhoea. Of in total 3,072 STI clinic attendees (98\% MSM), who were known to be HIV infected at entry in the clinic, 17\% were diagnosed with chlamydia and 15\% with gonorrhoea. These findings suggest the presence of considerable sexual risk behaviours in certain sub-populations of HIV-infected individuals.

The STI centre surveillance showed that the HIV test uptake had increased from 56\% in 2004 to 97\% in 2010 in STI clinic attendees who were not previously diagnosed with HIV. In 2009, the RIVM/CIb in collaboration with SHM and several STI centres initiated a study to document delay between primary diagnosis at an STI centre and reporting in care. The results are expected to provide more insight into HIV transmission dynamics and indicate potential interventions to reduce such delays.

Additional information is available STI/HIV publications of RIVM/CIb, including comprehensive reports published in English on an annual basis\textsuperscript{17}.

**Figure 3.** Total number of HIV tests and positivity rate of new HIV diagnoses by gender and sexual preference, STI centres, the Netherlands, 2004-2010 (Source: RIVM/CIb)


\textsuperscript{17} RIVM/CIb STI/HIV: \url{http://www.rivm.nl/cib/themas/soa/}
Screening programmes

Antenatal screening\(^{18}\)

Routine screening for HIV infection is offered to all pregnant women since January 2004. About 185,000 women are tested annually and in 2006-2009 the participation rate was 99.8%. The HIV testing is conducted according to the 'opting out' approach and is combined with other antenatal screening activities. There have been no reports of children born with HIV in the Netherlands in 2006-2008.

In 2009 a study of the effectiveness of antenatal screening for HIV was conducted. This study estimated that 0.05% (0.04-0.07%) of pregnant women in the Netherlands are infected with HIV. Forty percent of the HIV infections among pregnant women in 2006-2008 were newly diagnosed. The prenatal screening is estimated to prevent 5-10 HIV infections per year among newborns.

Blood screening\(^{19}\)

Sanquin Blood Supply Foundation screens blood donated by new and existing donors for HIV (and Hepatitis B and C, and syphilis). In 2010 no new donors were found to be HIV infected. One HIV infection was detected among existing donors (0.3 per 100000). These results may be biased by the exclusion of individuals with a higher risk for infection from the donor population. The costs associated with the HIV testing of blood products is about €6.8 per year\(^{20}\).

Specific studies in high-risk populations

The Amsterdam cohort studies monitor HIV incidence in self-selected populations of MSM and drug users in Amsterdam\(^{21}\). In this sample of MSM the HIV incidence was to 1.6 per 100 person-years in 2010, compared to 2.0 and 1.5 in 2009 and 2008, respectively. In contrast, the HIV incidence among drug users in this sample has declined to zero in recent years. These cohorts are useful to monitor trends in these groups but generalization may not be possible.

In 2002-2006 surveys were conducted in population groups at high risk for HIV infection, i.e. different ethnic minorities, sex workers, clients of sex workers and IDU\(^{22}\). Similar systematic surveillance efforts have not been conducted during the present reporting period. Following an evaluation of the surveys in 2007\(^{23}\), it was concluded that it would be more valuable and efficient to monitor trend in these high risk groups through routinely collected data from STI clinics, general practitioners (GP), methadone posts, etc.

In 2007/2008, in view of the high STI occurrence among HIV infected clients at STI centres, an STI prevalence study among HIV infected MSM was conducted. This revealed high occurrence of chlamydia or gonorrhoea (10.5%), syphilis (4.9%), infectious Hepatitis B (0.2%) and new Hepatitis C infections (0.5%).

---


\(^{20}\) Source: Sanquin Blood Supply Foundation


\(^{22}\) UNGASS Country Progress Report, the Netherlands, 2008
These results indicate frequent presence of risk behaviours and co-infections that could facilitate transmission of HIV. The results prompted the modification of guidelines to extend testing for syphilis and Hepatitis B and C in regular care. In 2011, the RIVM started, in collaboration with both regular health care and STI clinics, a study to assess the cost effectiveness of routine screening for Chlamydia and gonorrhoea in HIV infected MSM who are in specialised HIV care. Results are expected to guide discussion regarding how to address the high chlamydia or gonorrhoea prevalence in this group of people.

IV. National response to the AIDS epidemic

Human rights aspects such as universal access to comprehensive prevention programmes, treatment, care and support constitute a fundamental principle in the Netherlands. During the reporting period 2010-2011, we have published our first national policy plan STI/HIV 2012-2016 “To renew and reinforce” in which the overall HIV/AIDS policy and programmatic frameworks are explained. They have remained largely unaltered during 2010-2011, notwithstanding a number of important developments. This reflects the notion that appropriate services are usually deemed to be in place. Nonetheless, continuous commitment, monitoring and development are needed to ensure adequate policy and programmatic frameworks.

Stakeholders of the national response

The Ministry of VWS is primarily responsible for the development and implementation of HIV/AIDS policy and programmatic frameworks. However, related activities depend on the collaboration of a range of (sub-)national (non-)governmental stakeholders.

RIVM/CIb is affiliated with the Ministry of VWS and advises, where indicated in consultation with relevant stakeholders, civil society organisations and professionals, the Ministry about STI/HIV policy. RIVM/CIb conducts STI/HIV surveillance, control and research and has a coordinating role among stakeholders. Further to the above, RIVM/CIb assesses work plans of other organisations in the area of STI/HIV prevention and grants subsidies within the framework of national policy.

NGOs that receive governmental subsidies for HIV/AIDS-related programmes include: STI AIDS Netherlands (having programmes focusing on policy, professionals, general public, ethnic minorities, youth, as well as sex workers and their clients), Schorer (focusing on lesbians, gay men, bisexuals and transgenders), Mainline (focusing on drug users) and Rutgers WPF (focusing on sexual health). The government subsidises two organisations that concentrate on people living with HIV/AIDS (PLWHA): the HIV Vereniging Nederland.

References:

25 Ministry of VWS: http://www.minvws.nl/
26 RIVM/CIb: http://www.rivm.nl/cib/
27 STI AIDS Netherlands: http://www.soaaids.nl/
28 Schorer: http://www.schorer.nl/
29 Mainline: http://www.mainline.nl/
30 Rutgers World Population Foundation: http://www.rutgerswpf.nl/
31 HIV Vereniging Nederland: http://www.hivnet.org/
(focusing on information and support) and SHM32 (focusing on surveillance and research based on HIV patients in medical care). The governmental subsidies to these NGOs amount to about €10 million per year. The national ‘STI and sexual health platform’ meetings four times per year provide, among others, a platform for information exchange and coordination among NGO and governmental stakeholders.

Municipal authorities are legally co-responsible for STI/HIV-related prevention and care. These municipal tasks are typically conducted by the GGD. In 2009, part I of a handbook was completed to support health professionals at (sub-)national level in STI/HIV prevention and care33. Part II of the handbook is concerned with sexuality and reproduction.

Prevention

Primary prevention

The frameworks for STI/HIV prevention activities in the Netherlands are described in the national STI/HIV policy plan 2012-201634, as well as in the national STI/HIV prevention plan from 200435 and in the sexual health policy document from 200936. The promotion of safe (sexual) practices by provision of information is an important component of primary HIV/AIDS prevention. In this regard schools play an important role in informing youth and comprehensive sexuality education will be obligatory from 2012 onwards. The GGD and youth health care services are other settings where information about safe practices is disseminated.

Information about safe sex and prevention of STI/HIV is mainly communicated by means of targeted communication activities for specific groups such as MSM37, migrants38, sex workers39, IDU40, and youth41. In general, NGOs play key roles in primary prevention of HIV by provision of information, especially among high risk groups. Information activities utilize internet, printed materials, peer-to-peer education, outreach activities, etc.

Among drug users, harm reduction has proven to be a successful and cost-effective approach to HIV/AIDS prevention. Harm reduction is one component of a larger context which also includes prevention and treatment of the drug use per se. Methadone treatment programmes are available for opiate addicts and the majority of them participate in such programmes. The percentage of injecting drug use is relatively low (about 9% of heroin users). In 2009, there were about 115 needle exchange programmes throughout the Netherlands. There are no national data on the number of needles and syringes distributed to IDU although some information is available at subnational levels.

---

32 SHM: http://www.hiv-monitoring.nl/
37 http://www.schorer.nl/
38 http://www.soaaids-professionals.nl/soaaids_nl/etnisch
39 http://www.soaaids-professionals.nl/soaaids_nl/prostitutie
40 http://www.mainline.nl/
41 http://www.soaaids-professionals.nl/soaaids_nl/jongeren
Low-threshold access to information, testing and care

Promotion of HIV testing is conceived of as a crucial aspect of HIV prevention in the Netherlands. Persons who know they are HIV-infected can receive care and support, which can prevent further transmission of the infection.

As mentioned above, a large proportion (about 40%) of HIV-infected individuals is estimated to be unaware of their infection. In 2002, an ‘active testing policy’ was put in place, including antenatal screening (introduced 2004) and integration of the active testing policy in the STI/HIV-protocol for GPs42.

Moreover, since 2006 and in addition to the regular system for health care delivery and health promotion, there is a specific regulation (‘Aanvullende Curatieve Soa-bestrijding’ (ACS)) to provide low-threshold and free of charge STI/HIV testing and care. These services target high-risk groups. The services are provided at 29 STI centres spread over the country. Eight GGDs have a coordinating responsibility in their regions. The RIVM/CIb coordinates the implementation of the regulation. Quality documents support the delivery of high quality services. The associated costs are reimbursed in proportion to the number of identified STIs, which should stimulate a focus on high-risk groups. The costs for the regulation amount to about €23 million per year.

In 2009, to further stimulate HIV testing, it was decided that HIV testing according to the ‘opting out’ approach would be included in the above-mentioned ACS regulation. This means that a HIV test is performed as a standard. The patients are informed about the practice and may choose not to undergo the HIV test. The intensified HIV testing policy applies as of January 2010 and €300,000 per year has been reserved for this purpose.

In 2008, the ACS regulation was supplemented with an additional regulation that caters for young people under the age of 25 years (‘Aanvullende Seksualiteitshulpverlening’ (ASH)). The ASH regulation offers low-threshold services that can support youth with questions and problems regarding sexuality. Consultation services are offered with the support of governmental funds of about €3.5 million per year. In addition, a related website43 and a toolkit sexual health44 have been developed.

Since January 2012, the above-mentioned ACS regulation and ASH regulation have been integrated into one regulation, the ASG regulation (‘Aanvullende regeling Seksuele Gezondheidszorg’ (ASG)), providing additional care for sexual health. The aim of the integration of the two regulations is to enhance efficiency of the additional care provided and to improve the link between prevention and care. Moreover, another aim is financial maintenance of the ASG regulation.

Linkage between prevention and care

The national STI/HIV policy plan underlines the value of linking STI/HIV prevention and care. The setting of STI/HIV care presents an opportunity to reach people in high risk groups and to modify (risk) behaviours. By means of partner notification additional persons at risk for transmission may be given the opportunity to access testing and care. In the spirit of this notion, the integration of the ACS and ASH regulations into the ASG regulation took part in January 2012.

42 UNGASS Country Progress Report, the Netherlands, 2008
43 Sense website: http://www.sense.info/
44 RIVM/CIb. Toolkit seksuele gezondheid: http://preventieziektezorg.rivmvoorlichtingscentrum.nl/toolkitseksuelegezondheid/
Care, treatment and support

The general principle in the Netherlands is that everyone in need should receive appropriate health care. HIV/AIDS is not an exception in this context. The Netherlands Health Care Inspectorate (IGZ) supervises the access to and quality of care in the Netherlands.

HIV treatment is available for all patients with an indication (and has been since ART became available). The provision of treatment is legally regulated to ensure its high quality (‘Wet op Bijzondere Medische Verrichtingen’ (WBMV)). This legislation gives responsibility for the actual care to specialists situated in 25 HIV treatment centres throughout the Netherlands. Two treatment centres are specialized in paediatric treatment. In addition to specialized clinicians there are also specialised HIV/AIDS nurses who serve as case-managers.

In principle everyone who receives health care is charged by the health care provider for the care received, regardless of one’s nationality or legal status. However, the costs can be covered under a health insurance, an international social security regulation (like Regulation (EC) no. 1408/71) or a bilateral social security convention. In these latter cases the (E)111-procedure will apply. Under the Health Insurance Act (‘Zorgverzekeringswet’), all residents of the Netherlands are obliged to have a health insurance. Further to the above, the legislation prohibits insurance companies to decline health insurance for persons (including HIV-infected individuals) who are legally entitled/obliged to be insured. The Netherlands has a system where health insurers are compensated for predictable health care cost of their insured portfolio (risicovereveningssysteem). For this reason health insurers have no benefit in refusing people with a preexisting condition.

Asylum seekers and individuals without legal basis for residence

There are arrangements to provide HIV/AIDS prevention and care for (failed) asylum seekers in the Netherlands. The Dutch Government compensates the healthcare providers for the costs associated with healthcare for individuals with an ongoing request for asylum (currently approximately €3,800 per asylum seeker per year) (‘Regeling Verstrekkingen Asielzoekers’ and Regeling Zorg Asielzoekers’). The principle is that health care provided corresponds to standard care in the Netherlands. Asylum seekers accommodated in asylum centres receive, in collaboration with the GGD, information about STI/HIV prevention. In this regard a yearly plan is developed by the asylum centre and the GGD. Asylum seekers with an assigned asylum status must (as Dutch nationals) arrange their own insurance coverage.

The Netherlands does not regard HIV/AIDS alone as a reason for granting asylum, unless under exceptional circumstances pursuant to the European ‘Convention for the Protection of Human Rights and Fundamental Freedoms’. Should a person in need of treatment have to leave the country, Dutch authorities will if necessary establish contact with counterparts in the country of destination in order to facilitate continuation of treatment. Under certain circumstances, failed asylum seekers may be granted to stay in the Netherlands based on medical grounds, including HIV/AIDS. Signalling of medical problems at an early stage in the asylum process can help to avoid a gap between a failed asylum request and a decision regarding a request based on medical grounds. Furthermore, since January 2010 rejected asylum seekers with an ongoing request based on medical grounds are under certain circumstances entitled to accommodation and reimbursements for costs associated with health insurance. Should the request to stay in the Netherlands based on medical grounds be granted the (rejected) asylum seeker must (as Dutch nationals) arrange their own health insurance.

Persons who are illegally present in the Netherlands have to pay their own health care expenses. They are not covered by the Health Insurance Act, nor can they apply for social
assistance. Should these undocumented persons fail to pay for the cost of medical care, the health care provider can claim part of his costs from a national health insurance board ('College voor Zorgverzekeringen' (CVZ)). For this purpose the CVZ receives approximately €21 million per year out of the budget of the Ministry of VWS.

Notwithstanding the above-mentioned arrangements, unfamiliarity with the Dutch health care system may be a possible obstacle for asylum seekers and individuals without legal basis for residence. In asylum centres this is therefore given due consideration by provision of information, both routinely and in response to specific needs.

Supplementary services

As mentioned above, there are additional services that aim to provide low-threshold and free of charge access to STI/HIV testing and treatment for high-risk groups (ASG regulation). These services are intended to complement, not replace, the regular health care services. The regulation for the additional STI/HIV and sexual health care services do not differentiate between individuals based on nationality or legal status. As mentioned above, promoting testing is considered important for prevention purposes. Additionally, facilitating testing can lead to earlier HIV diagnoses and earlier treatment, thus benefitting the health of the infected individual as well.

Stigmatisation and discrimination

Stigmatisation and incidents of discrimination due to HIV infection is still a problem in Dutch society. This notion is supported by research from 2009 that suggests the presence of relatively widespread negative attitudes towards PLWHA and misconceptions about transmission of HIV45.

The government has sustained its policy to increase knowledge about STI/HIV and thereby, among other things, seeks to reduce stigmatisation and discrimination due to HIV/AIDS. The national policy STI/HIV plan 2012-2016 [ref] and the sexual health policy document from 2009 underlines the contributions in this regard of several NGOs that operate with governmental subsidies.

Also, the Ministry of VWS maintains the position that HIV-infected individuals should not be prosecuted for unsafe sex unless coercion, deception or disparity in terms of power are involved. This is consistent with the notion that everyone carries a responsibility for his or hers own health.

Since August 2009, legislation ('Arbeidsomstandighedenwet') against discrimination on the work place has been strengthened. Employers are obliged to have developed a policy based on risk assessment and evaluation to prevent and handle incidents of discrimination. Discrimination based on medical conditions or handicap (thus including HIV/AIDS) is prohibited. This applies to discrimination between employees and employers as well as among employees. The Labour Inspectorate ('Arbeidsinspectie') supervises the implementation of this legislation.

General social acceptance of risk groups, such as MSM, can contribute to the success of initiatives throughout the full spectrum of the HIV/AIDS prevention and response efforts. A

policy document, compiled by a coordinating ministry and with the contributions of several stakeholders, outlines the policy to enhance social acceptance of MSM.

Knowledge and behaviour change

A comprehensive national behavioural surveillance system is not established. Current insights about knowledge and behaviour in relation to HIV/AIDS are based on a range of different studies and surveillance activities. The results of different initiatives are usually not comparable due to methodological differences.

Nevertheless, existing findings illustrate that knowledge and intention to practice safe sex are frequently inadequately translated into actual safe sex. Thus, a major challenge is to foster a supportive environment for safe behaviour and build skills needed to translate intention into actual behaviour. The Centre for Healthy Living, part of the RIVM and established in 2007, has taken a step in this direction by establishing an inventory of different life-style interventions including descriptions of evidence regarding effectiveness.

High risk groups

Schorer performs an annual online behavioural survey, the Schorer Monitor, among MSM. The 2011 survey is based on 4,699 respondents primarily recruited through internet. The prospect of using a condom during anal intercourse with temporary partners was 67%. Unprotected anal intercourse with a temporary partner was reported by 36% of respondents who had had sexual contact with temporary partners during the previous six months. Determinants of unprotected anal intercourse with temporary partners were drug use, repeated sex contacts, disclosure of HIV status as well as being HIV positive. Post-exposure prophylaxis was familiar to 47% of respondents and 19% had vaguely heard about it.

Of MSM respondents with sexual experience, 78% had ever been tested for HIV infection, of which 46% during the past year. Fifteen percent of those ever tested were HIV positive, of which 45% went to controls at a HIV treatment centre. Of those being diagnosed with HIV for over one year, 84% received cART. The last HIV test had typically been performed at the GGD/STI clinic (55%), GP (32%) or in the hospital (5%). Results of the Schorer Monitor suggest an increase in the proportion of MSM ever tested for HIV (60% in 2006, 66% in 2008, 78% in 2011), as well as in the proportion of MSM recently tested.

Also see ‘Specific studies in high risk populations’ under section III ‘Overview of the AIDS epidemic’.

General population

In 2009 the Rutgers Nisso Group published a study about sexual and reproductive health. The study is based on a sample of 6,428 individuals in the age groups 15-70 years in the

---


47 RIVM/CGL website ‘Loket gezond leven’: http://www.loketgezondleven.nl/kwaliteit-van-interventies/beoordeelde-interventies/

Netherlands⁴⁹. This publication is a first follow-up of an initial study in 2006. The changes as compared to the study in 2006 are small, as anticipated in the light of the rather short time elapsed since 2006.

The results corroborate the notion that knowledge about STI/HIV among the Dutch population is relatively high. Of respondents below 50 years of age, 70-92% gives correct answers to statements about STI/HIV (e.g. refuting that washing after sex and using birth control reduce the risk for STI/HIV infection). A lower level of knowledge was noted among boys 15-18 years of age, less educated men and women and men among ethnic minorities.

A majority did not use a condom during the past six months during sexual intercourse with a steady partner (men 78%, women 80%), or during anal sex with a steady partner (men 85%, women 88%). During sexual contacts with temporary partners in the past six months, about 50% of men and women always used a condom, while about 25% used a condom sometimes or never, respectively. Condom use appeared to be lower among older age groups and among lower educated individuals.

The report of the Rutgers Nisso Group further indicated that about one-third of men, and a somewhat larger proportion of women, had ever been tested for an STI/HIV infection. About 10% had been tested during the past year. Women had primarily been tested by the GP (61%) while men were more likely to have undergone the test at the GGD/STI clinic (49%) as compared to at the GP (44%).

*Staff working in Dutch embassies in HIV-endemic areas*

Dutch Embassies in HIV-endemic areas are actively committed to the code of conduct of the International labour Organisation (ILO). All staff members have access to HIV/AIDS prevention and care.

**Impact alleviation**

Not applicable.

**V. Best practices**

- Surveillance data indicate that testing is becoming more widespread. This may be interpreted as an achievement attributable to the range of efforts that seek to stimulate HIV testing. These efforts include communication about the value of testing and maintenance of low-threshold access to HIV testing, in particular for high risk groups (ASG regulation).

- An enabling environment is fostered by the commitment and contributions of a range of (sub)national (non)governmental stakeholders that engage in constructive dialogue on a regular basis.

- Monitoring and evaluation are recognised as essential and are applied to inform development and implementation of the HIV/AIDS policy and programmatic frameworks.

In December 2011, the first national policy plan STI/HIV 2012-2016 “To renew and reinforce” was published. The integration of HIV/AIDS policy in a broader framework of sexual health is explained in this document and it is considered to offer potential for synergistic effects and the effective use of resources.

Harm reduction has been, and continuous to be, a successful component of HIV/AIDS prevention and control among IDU.

VI. Major challenges and remedial actions

Maintenance and further development of HIV/AIDS policy and programmatic frameworks pose a number of challenges that call for sustained commitment:

- Recognising that stigmatisation and discrimination of PLWHA is still a problem in Dutch society, this is acknowledged in the national STI/HIV policy plan as an important challenge.

- A large proportion (estimated about 40%) of HIV infected individuals are not diagnosed. This emphasizes the necessity of maintaining activities among risk groups and professionals and aiming to stimulate HIV testing. The incorporation of HIV testing as per the 'opting out' approach in STI centres (ASG regulation) as of January 2010 is one step in this direction.

- Notwithstanding significant communication efforts, sexual risk behaviours remain at high levels in certain groups, such as MSM and ethnic minorities. The high rates of HIV/STI co-infections in HIV infected MSM underline the need for sustained control measures targeting this group. Stimulating behaviour change in high risk groups remains a significant challenge. In the context of primary prevention, the principle of evidence-based practice could occasionally be further strengthened. The Centre for Healthy Living at the RIVM is anticipated to continue stimulating the use of evidence-based interventions in the area of HIV/AIDS prevention.

- STI/HIV testing, and hence also opportunities for prevention, typically occurs in the GP setting. The interaction between public health professionals and GPs in the benefit of STI/HIV control remains challenging. In general, partner notification deserves recognition to stimulate exploitation of the full potential of its application by different health professionals. These issues are addressed in our national STI/HIV policy plan.

- Financial and human resources are finite and pose limitations to the implementation of programmes. For example, the costs associated with providing low-threshold access to STI/HIV testing and treatment (ASG regulation) for high risk groups have increased in recent years. Discussion has been initiated regarding how to maximize health benefits of these services while keeping the related finances sound. The first step in this respect is the integration of the ACS and ASH regulations into one ASG regulation since January 2012.
VII. Support from the country’s development partners

Not applicable.

VIII. Monitoring and evaluation environment

As mentioned above, monitoring and evaluation are recognised as fundamentals to inform development and implementation of the HIV/AIDS policy and programmatic frameworks. The Ministry of VWS is responsible for overall monitoring and evaluation regarding the HIV/AIDS policy and programmatic frameworks. In practice, key responsibilities in this regard have been delegated to the RIVM/Cib that publishes an annual comprehensive surveillance report as well as briefer bi-annual interim reports. The former accommodates data and information from different STI/HIV surveillance activities and brings these together for a joint interpretation to inform national STI/HIV policy. Data and information sources include the registration of HIV patients at HIV treatment centres, managed by SHM, STI/HIV surveillance at STI centres and in GP networks, and screening of pregnant women and blood donors.

In addition, specific evaluations are conducted on a regular basis to assess the suitability of individual programmes/activities. For example, in the current reporting period evaluations have addressed the ACS and ASH regulations, respectively, that provide low-threshold access to information, testing and treatment for STI/HIV. Also, two initiatives have addressed the organisation50 and effectiveness of the antenatal screening51, respectively. As mentioned above, the IGZ supervises the access to and quality of care in the Netherlands.

NGOs contribute to the overall monitoring and evaluation system through research, surveillance and evaluations in their areas of expertise. For example, as illustrated above, the Rutgers WPF and Schorer have produced behavioural research/surveillance that is considered in the present report. NGOs serve an important function to identify weaknesses of the HIV/AIDS policy and programmatic frameworks and suggest possible solutions.

In addition to regular routine interactions, the RIVM/Cib organises a national expert meeting each year. The expert meeting offers an opportunity for (sub)national (non)governmental stakeholders to discuss recent surveillance data, research and other developments and exchange ideas, thereby informing future policy and activities in the area of STI/HIV. Furthermore, STI AIDS Netherlands organises the above-mentioned ‘STI and sexual health platform’ meetings on four occasions per year. Participants principally take part in these meetings in their capacity as experts, but they are also employed by Schorer, Rutgers Nisso Groep, HIV Vereniging Nederland, Mainline, GGD/STI clinics, RIVM/Cib and the Ministry of VWS. These meetings provide a platform for dialogue and thereby help address the challenge of maintaining an overview of undertakings by various stakeholders.

The government seeks to engage in international activities in the area of HIV/AIDS. This includes participation in fora of and cooperation with for example the European Centre for Disease Prevention and Control (ECDC), European Commission, World Health Organization


(WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS). These activities and related exchange of experiences can inspire and facilitate policy and programmatic development.

IX. Parts of the Dutch Kingdom in the Caribbean

The transition process for new administrative relations within the Kingdom of the Netherlands is completed. This resulted in closer ties between the Netherlands and three islands of the Netherlands Antilles (Bonaire, St. Eustatius and Saba – “Caribisch Nederland”), whereas the islands of Curaçao and St. Maarten have a more independent status within the Kingdom of the Netherlands. This situation has consequences for the HIV/AIDS policy and programmatic frameworks in the Dutch part of the Caribbean as the Netherlands will be more directly responsible for HIV/AIDS policy on the islands of “Caribisch Nederland”.

Combined data indicate that the cumulative total of HIV-infected individuals on the Dutch parts in the Caribbean amounts to 1,926 individuals (including preliminary data for 2008). Data sources include the Analytical Diagnostic Centre, Red Cross Blood Bank Foundation and the Central Bureau of Statistic of the Dutch parts of the Caribbean. These data translate into an increase of 197 (11%) HIV cases as compared to the cumulative total of 1,729 individuals in 2006\(^\text{52}\). The total number of HIV infected individuals appears to exhibit a relatively stable increase of about 100 persons per year. The total proportions of males and females are 57\% and 43\%, respectively. Sixty-four percent of the cumulative total of HIV infected individuals are attributed to the age groups of 25-44 years.

Since 2005 the Stichting HIV Monitoring follows HIV patients at the treatment centre on Curaçao. As of June 2011, 746 HIV patients were reported from this treatment centre, of whom 590 who were still alive. Reported data show that majority of the patients were male (61\%), were infected via heterosexual contact (67\%), and originated from the Dutch parts of the Caribbean (69\%). In total, 483 (74\%) patients had started cART.

The development of policy and programmatic frameworks for STI/HIV surveillance, prevention and care in the Dutch parts of the Caribbean pose challenges to concerned stakeholders. STI/HIV-related knowledge and skills among the public and professionals should be strengthened. Intensified surveillance and research are needed to shed further light on the characteristics of the epidemic, especially on risk groups and risk behaviours. The resulting information would be valuable to inform the development of policy and programmatic frameworks.

X. Contributions to international HIV/AIDS response

In 2011 the new government of the Netherlands has decided a reduction of the level of development assistance from 0.8\% to 0.7\% of its gross domestic product (GDP) and a focus on four priorities, among which Sexual and Reproductive Health and Rights, including HIV/AIDS. Since ODA is linked to GDP, future budgets might be affected by economic recession.

\(^{52}\) UNGASS Country Progress Report, the Netherlands, 2008
With regard to HIV/AIDS and SRHR development assistance, the Netherlands is among the largest contributors per capita, with an annual disbursement for SRHR and HIV/AIDS amounting to € 428 million in 2010 and € 370 million in 2011. The Dutch contribution is channeled through UNAIDS, United Nations Population Fund (UNFPA), the Global Fund to Fight AIDS, Tuberculosis and Malaria, government-to-government, public private and product development partnerships as well as through international and Dutch NGOs.

The Netherlands has an integrated policy with regard to HIV/AIDS and sexual and reproductive health which is informed by two distinct perspectives: human rights and prevention, which are seen as inextricably linked. Within these perspectives the focus is on young people and on marginalized groups. The Netherlands introduced the first youth participant in the point 7 delegation to the Global Fund.

The rights-based approach directs attention to the inequality of access to prevention, treatment and care services and on the discriminatory practices that rob people of the opportunity to assert their right to health. In addition to young people, the Dutch policy is particularly concerned with populations who are at increased risk of HIV and other infectious diseases such as people who use drugs (IDU), sex workers (SW), men who have sex with men (MSM), sexual minorities, prison inmates and mobile populations. The Netherlands is financing the “Bridging the Gaps” program of an Alliance of 7 Dutch NGOs, which have a unique and integrated approach towards the main key populations recognized in the Political Declaration of the UNGASS Aids in June 2011, namely MSM, SW and IDU.

The Dutch approach is characterized by pragmatism and informed by scientific research. The success of this policy is reflected in the Netherlands’ low rates of teenage pregnancies, abortions and HIV, especially among injecting drug users. These results add credibility to Dutch SRHR policy on the international arena. The objective of universal access to prevention, treatment and care, both with respect to SRHR and HIV/AIDS, is advocated across the entire spectrum of foreign policy by Dutch officials including the Ambassador for Sexual Health and Aids.
ANNEXES

ANNEX I: National Composite Policy Index questionnaire

Please submit your complete UNGASS Country Progress Report before 31 March 2012 using the UNGASS reporting website (www.unaids.org/UNGASS2010).

Please direct all enquiries related to UNGASS reporting to UNAIDS Monitoring and Evaluation Division at: ungassindicators@unaids.org.

If the Country Response Information System version 3 (CRIS3) or the UNGASS reporting website (www.unaids.org/UNGASS2010) is not used for submission of indicator data, please submit reports by 15 March 2010 to allow time for the manual entry of data into the Global Response Database in Geneva.